The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis

被引：0
|
作者：
Axel Svedbom
Johan Dalén
Moa Ivergård
Rebekah H. Borse
Christopher M. Black
Karin Luttropp
Sumesh Kachroo
机构：
[1] ICON Clinical Research,Real
[2] Merck & Co.,World Strategy and Analytics
[3] Inc.,Center for Observational and Real
来源：
The European Journal of Health Economics | 2020年 / 21卷
关键词：
Cost–benefit analysis; Medication persistence; Economic evaluation; Ankylosing spondylitis; Bechterew’s disease; I120;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：45 / 54
页数：9
相关论文
共 50 条
  • [1] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Svedbom, Axel
    Dalen, Johan
    Ivergard, Moa
    Borse, Rebekah H.
    Black, Christopher M.
    Luttropp, Karin
    Kachroo, Sumesh
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 45 - 54
  • [2] THE VALUE OF PERSISTENCE IN TREATMENT WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS FOR ANKYLOSING SPONDYLITIS
    Ivergard, M.
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Borse, R. H.
    Kachroo, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 840 - 841
  • [3] TNF-alpha inhibitors for ankylosing spondylitis
    Maxwell, Lara J.
    Zochling, Jane
    Boonen, Annelies
    Singh, Jasvinder A.
    Veras, Mirella M. S.
    Ghogomu, Elizabeth Tanjong
    Jandu, Maria Benkhalti
    Tugwell, Peter
    Wells, George A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (04):
  • [4] DETERMINANTS OF 12-MONTHS PERSISTENCE IN ANKYLOSING SPONDYLITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M. -C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 754 - 755
  • [5] Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Lamezec, Liliane
    Gouyette, Najat
    Ginoux, Marine
    Van Ganse, Eric
    Tubach, Florence
    Fautrel, Bruno
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
    I Orbán
    K Sevcic
    EV Kiss
    Pediatric Rheumatology, 9 (Suppl 1)
  • [7] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AND JAK INHIBITORS AMONG AUSTRALIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Puig, Andrea
    Chien, Tirian
    O'Sullivan, Catherine
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 24 - 24
  • [8] Neurosarcoidosis Induced by TNF-alpha Inhibitor in a Patient with Ankylosing Spondylitis
    Pak, Daod
    Askari, Elham
    Treidler, Simona
    NEUROLOGY, 2023, 100 (17)
  • [9] Determinants of 12-Months Persistence in Ankylosing Spondylitis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 514 - 515
  • [10] TNF-α inhibitors for the treatment of ankylosing spondylitis
    Wang, Michael Y.
    NEUROSURGERY, 2006, 59 (02) : N7 - N7
12345